Elenbecestat trials to be discontinued for early Alzheimer’s disease: industry news round-up

This week in industry we’re covering some of the biggest stories that have made the headlines, including the decision to discontinue the elenbecestat trials for Alzheimer’s disease and Toca 511/Toca FC failing to meet their primary endpoint for high-grade glioma. In addition to this, Novartis (Basel, Switzerland) have presented their findings from an earlier report where they indicated that ofatumumab is superior to Aubagio® for relapsing multiple sclerosis (MS). Discover more about our selection of this week’s highlights below (click to navigate): Elenbecestat trials to be discontinued for early Alzheimer’s disease Ofatumumab is superior to Aubagio for relapsing multiple sclerosis...